Author:
Pratap Veeresh Babu,Padamatinti Anvesh Nag,Mudunuri Ganga Raju,Gotika Vishnu Priya
Abstract
Depression is a heterogeneous mood disorder that has been classified and treated in a variety of ways. Despite the fact that a variety of synthetic medications are utilized as conventional treatment for clinically depressed patients, these drugs have side effects that can jeopardize the therapeutic outcome. In recent decades, there has been a rise in research and interest in the psychopharmacology of natural treatments. Thus, it’s worthwhile researching for antidepressants derived from plants that have a demonstrated effect and a favorable benefit-to-risk ratio. By virtue of their medicinal constituents, a variety of medicinal plants and medicines produced from these plants have exhibited antidepressant properties. As a result, major pharmaceutical companies are currently researching plant materials extensively for their possible medical benefit. Depression is caused by low levels of monoamines such as noradrenaline, dopamine, and serotonin in the brain. Therefore, treatments that restore lowered levels of these monoamines in the brain by blocking monoamine oxidase or decreasing reuptake of these neurotransmitters could be beneficial in the treatment of depression. The current review focuses on medicinal plants and plant-based formulations that have been shown to have antidepressant effect in both animal and human studies.
Reference47 articles.
1. Gin Malhi S, John Mann J. Depression. Lancet 2018;392:2299-12.
2. Wright S, Strunk A, Garg A. Prevalence of depression among children, adolescents, and adults with hidradenitis suppurativa. J Am Acad Dermatol 2021:S0190-9622(21)01947-2.
3. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, Rahman Z, Ring RH, Schechter LE. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther. 2007;113(1):134-53.
4. Kessler RC. Epidemiology of women and depression. J Affect Disord 2003;74:5-13.
5. Rickards H. Depression in neurological disorders: Parkinson’s disease, multiple sclerosis, and stroke. J Neurol Neurosurg Psychiat 2005;76:i48-52.